Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale
Advertisement
Articles by Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale
Takeaways on Treatment of Early-Stage NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Risk of Pneumonitis Post-Chemoradiation in Stage 3 NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Considering PD-L1 and EGFR Status With I/O in Stage 3 NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
PACIFIC Trial in Stage 3 NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Future of Neoadjuvant I/O in ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Neoadjuvant I/O for ES NSCLC: Key Trials from ESMO 2020
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Key Trials in Neoadjuvant I/O for ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Role of Neoadjuvant I/O in ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Patient Selection: Adjuvant Therapy and Testing for ES NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Phase 3 ADAURA Study: EGFR-Mutated NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Role of Postoperative Radiotherapy in Early Stage NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Neoadjuvant Chemotherapy in Early-Stage NSCLC
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Treatment of Early-Stage NSCLC: Current Standard of Care
ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospitale,Ticiana Leal, MD, University of Wisconsin-Madison,Jarushka Naidoo, MBBCh, Beaumont Hospital,Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center,Jun Zhang, MD, PhD, University of Kansas Medical Center
Advertisement
Latest Updated Articles
Neoadjuvant I/O for ES NSCLC: Key Trials from ESMO 2020October 26th 2020
Takeaways on Treatment of Early-Stage NSCLCOctober 26th 2020
Phase 3 ADAURA Study: EGFR-Mutated NSCLCOctober 26th 2020
Neoadjuvant Chemotherapy in Early-Stage NSCLCOctober 26th 2020
PACIFIC Trial in Stage 3 NSCLCOctober 26th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5